VSTM - Verastem, Inc.
| Previous Close | 1.3500 |
| Open | 1.3400 |
| Bid | 0.0000 x 3200 |
| Ask | 0.0000 x 900 |
| Day's Range | 1.3300 - 1.3700 |
| 52 Week Range | 1.1600 - 10.3500 |
| Volume | 383,561 |
| Avg. Volume | 1,707,496 |
| Market Cap | 100.09M |
| Beta (3Y Monthly) | 2.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.8440 |
| Earnings Date | Nov 8, 2018 - Nov 9, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.83 |
- Thomson Reuters StreetEvents
Edited Transcript of VSTM earnings conference call or presentation 1-Aug-19 8:30pm GMT
Q2 2019 Verastem Inc Earnings Call
Motley FoolVerastem Inc (VSTM) Q2 2019 Earnings Call Transcript
VSTM earnings call for the period ending June 30, 2019.
- Zacks
Verastem (VSTM) Reports Q2 Loss, Tops Revenue Estimates
Verastem (VSTM) delivered earnings and revenue surprises of 2.04% and 41.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Verastem Oncology Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress
Company Reports $3.0 Million in Net Product Revenues from COPIKTRA®; Raises Product Revenue Guidance for 2019
- Benzinga
The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 29) Acasti Pharma Inc (NASDAQ: ACST ) Array Biopharma Inc ...
- Business Wire
Verastem Oncology Appoints Brian Stuglik as Chief Executive Officer
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that Brian Stuglik, a member of the Board of Directors, has been named Chief Executive Officer (CEO). “Brian brings deep commercial and biopharmaceutical leadership experience that we believe will accelerate the growth of COPIKTRA™ and progress overall company goals,” said Michael G. Kauffman, MD, PhD, Verastem Oncology’s Lead Director. Mr. Stuglik has more than three decades of experience in US and International pharmaceutical development, product strategy and commercialization, with a focus on Oncology.
- Benzinga
The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 25) Akero Therapeutics Inc (NASDAQ: AKRO ) Anika Therapeutics ...
- Business Wire
Verastem Oncology Signs an Exclusive License Agreement with Sanofi for the Development and Commercialization of COPIKTRA® (duvelisib) in Russia and CIS, Turkey, the Middle East and Africa
Verastem, Inc. (VSTM) operating as Verastem Oncology, (or “the Company”), today announced their entry into an exclusive licensing agreement with Sanofi to develop and commercialize Verastem Oncology’s COPIKTRA® (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma, for the treatment of all oncology indications in Russia and CIS, Turkey, the Middle East and Africa. Verastem Oncology is also eligible to receive up to an additional $42 million USD in development and sales milestone payments, plus double-digit percentage royalties based on future net sales of COPIKTRA in the licensed territories. Sanofi will receive exclusive rights to develop and commercialize COPIKTRA, and hold the marketing authorization and product license for COPIKTRA, in the licensed territories.
- Business Wire
Verastem Oncology to Announce Second Quarter 2019 Financial Results and Corporate Update on August 1, 2019
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the Company will host a conference call and webcast on Thursday, August 1, 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the second quarter ended June 30, 2019. The live, listen-only webcast of the conference call can be accessed by visiting the investors section of the Company's website at www.verastem.com. A replay of the webcast will be archived on the Company's website for 90 days following the call.
- Simply Wall St.
What Kind Of Shareholders Own Verastem, Inc. (NASDAQ:VSTM)?
A look at the shareholders of Verastem, Inc. (NASDAQ:VSTM) can tell us which group is most powerful. Generally...
- Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of options to purchase 104,000 shares of its common stock to five new employees. The awards were granted as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $1.41 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on July 1, 2019 and vest at a rate of 25% on the one-year anniversary of his or her date of hire, and thereafter, at a rate of 6.25% of the shares subject to the options at the end of each successive three-month period, provided that the employee continues to serve as an employee of or other service provider to Verastem Oncology on each such vesting date.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Verastem Inc (VSTM)
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged during the first quarter. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 40% and 25% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted […]
- Zacks
Verastem Up on Positive Data From Early-Stage Copiktra Study
Verastem (VSTM) presents encouraging data from an early-stage study evaluating its recently approved drug, Copiktra, for treating peripheral T-cell lymphoma.
- Benzinga
Verastem Shares Response Rate From COPIKTRA Data
Verastem Oncology (NASDAQ: VSTM ) presented COPIKTRA data showing response rates of 44% to 57%, including complete response rates of 15% to 22% in patients with relapsed or refractory peripheral T-cell ...
- Business Wire
Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data in Peripheral T-Cell Lymphoma at the 2019 International Conference on Malignant Lymphoma
Steven Horwitz, MD, Gives Oral Presentation Highlighting Phase 1 Duvelisib Data in Patients with Relapsed or Refractory PTCL
- Zacks
The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure
The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure
- Business Wire
Verastem Oncology Announces Leadership Changes
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that Robert Forrester has decided to step down as President and Chief Executive Officer. Mr. Forrester has agreed to continue serving Verastem Oncology in an advisory capacity.
- Zacks
Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal
A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.
- Business Wire
Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data at the European Hematology Association 2019 Annual Meeting
In CLL/SLL Patients in the DUO Study, Duvelisib Treatment Rapidly Increased Lymphocytes and Resulted in Shrinkage of Lymph Nodes, With 86% of Patients Achieving a Lymph Node Respon
- Business Wire
Verastem Oncology to Present at the Jefferies 2019 Global Healthcare Conference
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the Company will present at the Jefferies 2019 Global Healthcare Conference on Friday, June 7, 2019 at 11:30 a.m. EDT in New York, NY. A live webcast of the presentation will be available on the investors section of the Company’s website at www.verastem.com. Verastem Oncology (VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer.
- Simply Wall St.
Did You Manage To Avoid Verastem's (NASDAQ:VSTM) Devastating 85% Share Price Drop?
We're definitely into long term investing, but some companies are simply bad investments over any time frame. We...
- Thomson Reuters StreetEvents
Edited Transcript of VSTM earnings conference call or presentation 9-May-19 8:30pm GMT
Q1 2019 Verastem Inc Earnings Call
- Business Wire
Verastem Oncology to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 20th Annual B. Riley FBR Institutional Investor Conference on Thursday, May 23, 2019 at 1:30 p.m. PDT in Beverly Hills, CA. A live webcast of the presentation will be available on the investors section of the Company’s website at www.verastem.com. Verastem Oncology (VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer.
- Business Wire
Verastem Oncology to Present New COPIKTRA™ (Duvelisib) Dose Modification Data from Patients Treated in the Phase 3 DUO Study
Abstract Highlights the Effect of Dose Modification on Response to COPIKTRA in Adult Patients with CLL/SLL After At Least Two Prior Therapies
Motley FoolVerastem Inc (VSTM) Q1 2019 Earnings Call Transcript
VSTM earnings call for the period ending March 31, 2019.
